Gracell Biotechnologies to Present Three Innovative TIL Therapy Research Updates at SITC 2024

Oct 22, 2024 08:00 CST Updated 08:00

Grit Biotherapeutics

Developer of Immunotherapy Drugs for Solid Tumors

From November 6 to 10 local time, the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held in Houston, USA.Gracell Biotechnologies Attends SITC 2024 and Shares Three Research Achievements from Internal Development and Collaborative Projects: (1) The clinical trial design for Grail Bio's next-generation gene-edited TIL GT300; (2) Application of PDO to enrich tumor-specific TIL; (3) Use of Cas12b technology in preparing next-generation gene-edited TIL. More details on the research achievements will be introduced in this official account later. Stay tuned.

Title:Trial in Progress: First-in-Human Study of Next-Generation Dual-KO TIL Therapy GT300 in Patients with Advanced Solid Tumors

Display Number: 686

Exhibition Time (Local Time): Thursday, Nov. 7 & Friday, Nov. 8

Location: Exhibit Halls A B George R. Brown Convention Center

Title:Generation of tumor-reactive T cell-enriched Tumor Infiltrating Lymphocytes (TILs) product with autologous patient-derived organoid(PDO)

Display Number: 465

Display Time (Local Time): Thursday, Nov. 7 & Friday, Nov. 8

Location: Exhibit Halls A B George R. Brown Convention Center

Title:Development of a next-generation dual-KO TIL product GT300 with AaCas12bMax nuclease

Display Number: 464

Exhibition Time (Local Time): Thursday, Nov. 7 & Friday, Nov. 8

Location: Exhibit Halls A B George R. Brown Convention Center

About Gravel Bio

Grail Bio was founded in 2019 as an innovative pharmaceutical company focused on tumor immunotherapy, with a research and development pipeline represented by TIL (Tumor-Infiltrating Lymphocyte) drugs. Grail Bio has completed multiple rounds of equity financing, receiving support from several well-known venture capital funds both in China and internationally. The GT101 injection, independently developed by Grail Bio, is the first TIL drug in China to be approved for registrational clinical trials and is currently in a pivotal Phase II clinical trial. Grail Bio's GT201 injection, the world’s first membrane-bound IL-15 complex-engineered TIL product, has completed dual IND submissions in both China and the U.S. The company’s core R&D platforms include the StemTexp® stem-like TIL expansion technology platform, the StaViral® stable viral production system, the ImmuT Finder® immunomodulatory target discovery platform, and the KOReTIL® high-efficiency gene knockout system, which have enabled the development of a series of next-generation gene-edited TIL therapeutics. Grail Bio possesses internationally leading technical reserves and industrial resources, aiming to create groundbreaking cell-based therapies for solid tumors, bringing new hope to cancer patients worldwide.